<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18838" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Carbamazepine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maan</surname>
            <given-names>Jasdave S.</given-names>
          </name>
          <aff>American University of Antigua</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Duong</surname>
            <given-names>Truc vi H.</given-names>
          </name>
          <aff>Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jasdave Maan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Truc vi Duong declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18838.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Carbamazepine is used to manage and treat epilepsy, trigeminal neuralgia, and acute manic and mixed episodes in bipolar I disorder. Indications for epilepsy are specifically for partial seizures with complex symptomatology (psychomotor, temporal lobe), generalized tonic seizures (grand mal), and mixed seizure patterns. This activity will highlight off-label uses, mechanism of action, dosing, adverse effects, contraindications, and other key factors regarding carbamazepine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at increased risk for adverse dermatological effects from carbamazepine.</p></list-item><list-item><p>Outline the indications for carbamazepine.</p></list-item><list-item><p>Summarize the management of carbamazepine toxicity.</p></list-item><list-item><p>Describe the importance of coordinated activity among interprofessional team members to improve patient outcomes in patients treated with carbamazepine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18838&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18838">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18838.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Carbamazepine is FDA indicated for epilepsy, trigeminal&#x000a0;neuralgia, and acute manic and mixed episodes in bipolar I disorder.<xref ref-type="bibr" rid="article-18838.r1">[1]</xref><xref ref-type="bibr" rid="article-18838.r2">[2]</xref>&#x000a0;Indications for epilepsy are specifically for partial seizures with complex symptomatology (psychomotor, temporal lobe), generalized tonic seizures (grand mal), and mixed seizure patterns.<xref ref-type="bibr" rid="article-18838.r1">[1]</xref> Carbamazepine is not indicated for absence seizures.<xref ref-type="bibr" rid="article-18838.r3">[3]</xref> Carbamazepine is FDA indicated as a first-line treatment for trigeminal neuralgia or tic douloureux. A systemic review shows the efficacy of carbamazepine extended-release in bipolar I mania in patients with acute manic or mixed episodes.<xref ref-type="bibr" rid="article-18838.r4">[4]</xref></p>
        <p>Carbamazepine is used off-label for refractory schizophrenia. Simple well designed trials have shown efficacy in patients with schizophrenia with EEG abnormalities, schizophrenia with violent episodes, and schizoaffective disorder. It improves both positive and negative symptoms in schizophrenic patients.<xref ref-type="bibr" rid="article-18838.r5">[5]</xref> Other off-label uses of this drug include treating restless leg syndrome and decreasing agitation and aggression in patients with dementia.<xref ref-type="bibr" rid="article-18838.r6">[6]</xref><xref ref-type="bibr" rid="article-18838.r7">[7]</xref> Another prominent off-label use of this drug is the treatment of neuropathic pain and fibromyalgia.<xref ref-type="bibr" rid="article-18838.r8">[8]</xref> In patients with moderate to severe alcohol withdrawal syndrome, carbamazepine has shown clinical efficacy in treatment. However, this indication does not have approval from the FDA, and it has not been shown to prevent alcohol withdrawal seizures compared to benzodiazepines.<xref ref-type="bibr" rid="article-18838.r9">[9]</xref>&#x000a0;Carbamazepine is also used off-label for maintenance therapy for bipolar disorder.&#x000a0;In a comparison trial among carbamazepine, lithium, and valproic acid, patients taking carbamazepine has a higher risk for relapse, yet not elevated by a significant amount.<xref ref-type="bibr" rid="article-18838.r10">[10]</xref></p>
      </sec>
      <sec id="article-18838.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Carbamazepine modulates&#x000a0;voltage-gated sodium channels (VGSC), causing inhibition of action potentials and decreased synaptic transmission. Similar to other anti-convulsions, carbamazepine is suggested to bind to the alpha subunit of VGSC, specifically at a binding pocket formed by the external pore loop and the pore-lining part of domain IV.<xref ref-type="bibr" rid="article-18838.r11">[11]</xref> Researchers proposed that carbamazepine keeps sodium channels in inactivated states, leading to fewer channels to open and thus inhibits the generation of action potentials.<xref ref-type="bibr" rid="article-18838.r1">[1]</xref>&#x000a0; Carbamazepine also binds to other voltage-gated ion channels, such as voltage-gated calcium channels.<xref ref-type="bibr" rid="article-18838.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18838.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Carbamazepine is available as conventional tablets (100mg, 200mg), extended-release tablets (100 mg, 200 mg, 300 mg, and 400 mg), suspensions, and solutions. Extended-release tablets cannot be crushed or chewed. Tegretol and Tegretol XR should be taken with food, while Carbatrol capsules may be opened and sprinkled on food. Initial dosing is 200 mg twice daily in adults and 100 mg twice daily in children under 12, slowly increasing over time to a minimum effective level. Minimum effective levels in adults and children over 12 years are 800 mg to 1200 mg daily for the treatment of epilepsy. In children from six to 12 years, the effective level for treatment of epilepsy is 400 mg to 800 mg daily.<xref ref-type="bibr" rid="article-18838.r12">[12]</xref></p>
      </sec>
      <sec id="article-18838.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common side effects of carbamazepine include dizziness, drowsiness, ataxia, nausea, and vomiting. Although rarer in occurrence, this comes with a black box warning for several severe dermatologic reactions. In patients of Han Chinese ancestry, studies have indicated a strong association between the <italic toggle="yes">HLA-B*1502</italic> gene and Steven Johnson syndrome/toxic&#x000a0;epidermal necrolysis (SJS/TEN). Studies have shown no increased risk with this gene and SJS/TEN in Iranian patients.<xref ref-type="bibr" rid="article-18838.r13">[13]</xref> A meta-analysis of 11 studies with 343 cases of carbamazepine-induced SJS/TEN showed <italic toggle="yes">HLB-B*4001</italic>, <italic toggle="yes">HLB*4601</italic>, and <italic toggle="yes">HLB*5801</italic> genes were strong protective factors. Patients&#x000a0;of Han Chinese ancestry should undergo testing for the <italic toggle="yes">HLA-B*1502</italic> gene. Up to 90 % of patients on carbamazepine who have this reaction experience it within the first few months of treatment. Another important allele to consider with this medication is <italic toggle="yes">HLA*3101</italic>. This allele is present in Japanese, Korean, and European ancestry.<xref ref-type="bibr" rid="article-18838.r1">[1]</xref><xref ref-type="bibr" rid="article-18838.r14">[14]</xref>&#x000a0;Retrospective studies show a significantly increased incidence of dermatologic reactions such as Stevens-Johnson syndrome, toxic epidemic necrolysis, maculopapular eruptions, and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome).<xref ref-type="bibr" rid="article-18838.r1">[1]</xref></p>
        <p>Carbamazepine has another black box warning on agranulocytosis and aplastic anemia.<xref ref-type="bibr" rid="article-18838.r10">[10]</xref>&#x000a0;Other serious side effects include central nervous system depression, hepatotoxicity, confusion, renal toxicity, suicidal ideation, and hyponatremia. Hyponatremia is mild, transient, and reversible.<xref ref-type="bibr" rid="article-18838.r15">[15]</xref></p>
        <p>Due to the mild anticholinergic activity, carbamazepine can increase the risk of delirium in the elderly population. This effect can also lead to urinary retention, increased intraocular pressure, and constipation.<xref ref-type="bibr" rid="article-18838.r16">[16]</xref></p>
        <p>Carbamazepine can exacerbate heart failure patients or even lead to cardiac dysfunction in healthy patients due to its tendency to cause homocysteinemia. Homocysteine is commonly known to increase the risk of cardiovascular disease. Patients with cardiac conduction issues have a higher risk of undergoing atrioventricular (AV) heart block. The use of this drug in patients with an abnormal ECG should be avoided to elude potential second and third-degree AV heart block.</p>
        <p>This drug is teratogenic and is a category D drug in pregnancy. Although contraindications to carbamazepine do not include pregnancy, clinicians should only use it if the benefits outweigh the increased risk of congenital malformation. Such malformations include spina bifida, craniofacial defection, cardiovascular cutaneous malformation, hypospadias, and developmental delays. Plasma level is reduced during pregnancy, likely related to increased metabolism. Carbamazepine can cross the placenta,&#x000a0;and this drug can also be transferred through breast milk in nursing infants, prompting&#x000a0;the need to decide&#x000a0;whether to discontinue nursing or discontinue the drug in the mother.<xref ref-type="bibr" rid="article-18838.r17">[17]</xref><xref ref-type="bibr" rid="article-18838.r18">[18]</xref>&#x000a0;Carbamazepine has a relatively low teratogenic effect in comparison to Valproic acid.<xref ref-type="bibr" rid="article-18838.r19">[19]</xref>&#x000a0;Precautions should be taking in mixed seizure disorder that includes atypical absence seizures. There is an increased frequency of generalized convulsions in this group of patients with this drug.</p>
      </sec>
      <sec id="article-18838.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Carbamazepine is contraindicated in patients with bone marrow depression and hypersensitivity to this drug or tricyclic compounds such as amitriptyline.<xref ref-type="bibr" rid="article-18838.r20">[20]</xref> Before administration, monoamine oxidase inhibitors should be discontinued for a minimum of 14 days. Usage carbamazepine and nefazodone together may result in insufficient plasma concentration of nefazodone. Carbamazepine is contraindicated in use with nefazodone.</p>
      </sec>
      <sec id="article-18838.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Carbamazepine is metabolized in the liver to carbamazepine-10, 11-epoxide, which is the active metabolite the leads to pharmacological action.<xref ref-type="bibr" rid="article-18838.r1">[1]</xref> Before administering this drug, a few labs merit consideration. Screening for <italic toggle="yes">HLA-A*3101</italic> and <italic toggle="yes">HLA-B*1502</italic> genotypes should be conducted alongside a pregnancy test.<xref ref-type="bibr" rid="article-18838.r1">[1]</xref> Complete blood counts (CBC)&#x000a0;are necessary at baseline, and therapy should stop if a low white blood count or platelet count appears on subsequent lab results. Liver enzymes require an assessment to avoid acute liver failure. This drug shows an increased risk for suicidal thoughts and behavior, prompting psychiatric evaluation of patients of this drug if possible. Patients with increased intraocular pressure should have periodic eye examinations to look out for specific ocular changes, focusing on the slit lamp, fundoscopy, and tonometry.&#x000a0; This drug has shown increased porphyrin production in rodents. Patients with a history of porphyrias, such as acute intermittent porphyry, variegate porphyria, and porphyria cutanea tarda, should be carefully monitored to avoid acute attacks.</p>
        <p>Clinicians should discontinue this drug at the first sign of a drug-related rash, any evidence of significant bone marrow depression, or worsening hepatic damage. Withdrawal should be gradual as immediate withdrawal severely increases the risk for status epilepticus. Abrupt discontinuation leads to severe hypoxia that can be fatal, especially to a pregnant woman. Even smaller seizures from withdrawing the drug too fast can lead to significant damage to the fetus.&#x000a0;Routine screening should be ordered with a pregnant woman to assess for possible defects.</p>
      </sec>
      <sec id="article-18838.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In adults, doses of carbamazepine exceeding 24 grams have correlated with fatal outcomes. Acute toxicity appears after 1 to 3 hours of intake and presents with neuromuscular disturbances. Patients have impaired consciousness leading to coma, tremor, restlessness, athetoid movements, psychomotor disturbances, dizziness, drowsiness, mydriasis, and nystagmus. Initially, patients experience hyperreflexia, but during intoxication, they progress into a state of hyporeflexia. Cardiac, vascular signs are generally mild with low toxicity, but with doses higher than 60 grams, severe cardiac dysfunction can occur.&#x000a0;In cases of acute toxicity, respiratory depression, ECG abnormalities, tachycardia, shock, and urinary retention require monitoring and management to avoid end-organ damage. Treatment of an overdose focuses on eliminating the drug by inducing vomiting, gastric lavage, activated charcoal, and forced diuresis. Gastric lavage is indicated even after 4 hours of indigestion.<xref ref-type="bibr" rid="article-18838.r21">[21]</xref> Seizures caused by carbamazepine poisoning should receive treatment with benzodiazepines such as diazepam.</p>
      </sec>
      <sec id="article-18838.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Carbamazepine is often prescribed by primary care providers, neurologists, and pain specialists. When prescribing this medication, it is essential to inform the patient of the potential adverse effects. Therefore, patients require the attention of an entire interprofessional healthcare team that includes clinicians, nurses, and pharmacists, all coordinating their activities and engaging in open information-sharing regarding developments in the patient's case. This interprofessional teamwork will improve therapeutic outcomes and minimize adverse effects for patients receiving carbamazepine therapy. [Level 5]</p>
        <p>The most common side effects of carbamazepine include dizziness, drowsiness, ataxia, nausea, and vomiting. Although rarer in occurrence, this comes with a black box warning for several severe dermatologic reactions. In patients of Han Chinese ancestry, studies have indicated a strong association between the&#x000a0;<italic toggle="yes">HLA-B*1502</italic>&#x000a0;gene and Steven Johnson syndrome/toxic&#x000a0;epidermal necrolysis (SJS/TEN).&#x000a0;</p>
        <p>If the drug has been prescribed for seizures, then the primary care providers should not alter the dose without first consulting with the patient's neurologist. Patients should be warned not to combine this agent with other antiseizure medications, alcohol, or illicit drugs.</p>
        <p>Due to CYP activities, co-administering carbamazepine with oral contraceptive hormone, warfarin, nefazodone, etc., can affect plasma levels. Carbamazepine can auto-induce its metabolism, thus reducing the half-life on repeated doses.</p>
        <p>Carbamazepine is one of the first anticonvulsants used to treat bipolar disorder. It is usually well-tolerated in comparison to Lithium and valproic acid. The new extended-release capsule approved by the FDA in 2004 is developed to decrease the fluctuation of plasma levels and lower the incidence of adverse effects.</p>
      </sec>
      <sec id="article-18838.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18838&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18838">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18838/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18838">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18838.s11">
        <fig id="article-18838.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Carbamazepine structure Contributed by the Public Domain</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="512px-Carbamazepine.svg" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18838.s12">
        <title>References</title>
        <ref id="article-18838.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Carbamazepine Therapy and <italic>HLA</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2015</year>
            <month>10</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">28520367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceron-Litvoc</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Geddes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Litvoc</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Lima</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials.</article-title>
            <source>Hum Psychopharmacol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-28</page-range>
            <pub-id pub-id-type="pmid">19053079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wallengren</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Petrou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The mechanism of carbamazepine aggravation of absence seizures.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>319</volume>
            <issue>2</issue>
            <fpage>790</fpage>
            <page-range>790-8</page-range>
            <pub-id pub-id-type="pmid">16895979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Extended-release carbamazepine for acute bipolar mania: a review.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2006</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>283</fpage>
            <page-range>283-9</page-range>
            <pub-id pub-id-type="pmid">16801991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Englisch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zink</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment-resistant Schizophrenia: Evidence-based Strategies.</article-title>
            <source>Mens Sana Monogr</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-32</page-range>
            <pub-id pub-id-type="pmid">22654380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winkelmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>H&#x000f6;gl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Salminen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Trenkwalder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sampaio</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)<sup>&#x000a7;</sup>.</article-title>
            <source>Mov Disord</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>1077</fpage>
            <page-range>1077-1091</page-range>
            <pub-id pub-id-type="pmid">29756335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tariot</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Erb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Podgorski</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jakimovich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.</article-title>
            <source>Am J Psychiatry</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>155</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-61</page-range>
            <pub-id pub-id-type="pmid">9433339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kalso</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Apr</month>
            <day>10</day>
            <volume>2014</volume>
            <issue>4</issue>
            <fpage>CD005451</fpage>
            <pub-id pub-id-type="pmid">24719027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latifi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Messer</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of Tiapride and Carbamazepine Combination Therapy in Reducing Alcohol Withdrawal Symptoms: A Systematic Review and Meta-Analysis.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>209</fpage>
            <page-range>209-216</page-range>
            <pub-id pub-id-type="pmid">30522144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peselow</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Clevenger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>IsHak</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>218</fpage>
            <page-range>218-23</page-range>
            <pub-id pub-id-type="pmid">26523730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gambeta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chichorro</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zamponi</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments.</article-title>
            <source>Mol Pain</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>16</volume>
            <fpage>1744806920901890</fpage>
            <pub-id pub-id-type="pmid">31908187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gierbolini</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giarratano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benbadis</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Carbamazepine-related antiepileptic drugs for the treatment of epilepsy - a comparative review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2016</year>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>885</fpage>
            <page-range>885-8</page-range>
            <pub-id pub-id-type="pmid">26999402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tonekaboni</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jafari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mansouri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jabbehdari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eftekhari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chavoshzadeh</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Abdollah Gorji</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mesdaghi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*1502 in Iranian Children with Anticonvulsant Drugs-Induced Skin Reactions.</article-title>
            <source>Iran J Child Neurol</source>
            <year>2017</year>
            <season>Spring</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>26</fpage>
            <page-range>26-30</page-range>
            <pub-id pub-id-type="pmid">28698724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.</article-title>
            <source>Pharmacogenomics</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>1543</fpage>
            <page-range>1543-6</page-range>
            <pub-id pub-id-type="pmid">18855540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandelman</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Review of carbamazepine-induced hyponatremia.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-33</page-range>
            <pub-id pub-id-type="pmid">8208974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hmouda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ben Salem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bouraoui</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Carbamazepine-induced urinary retention.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>833</fpage>
            <page-range>833-4</page-range>
            <pub-id pub-id-type="pmid">18078476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertilsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of carbamazepine.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1978</year>
            <season>Mar-Apr</season>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-43</page-range>
            <pub-id pub-id-type="pmid">346287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vajda</surname>
                <given-names>FJE</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lander</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Eadie</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Is carbamazepine a human teratogen?</article-title>
            <source>J Clin Neurosci</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>23</volume>
            <fpage>34</fpage>
            <page-range>34-37</page-range>
            <pub-id pub-id-type="pmid">26521756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ornoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weinstein-Fudim</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ergaz</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants, Antipsychotics, and Mood Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with Depression.</article-title>
            <source>Birth Defects Res</source>
            <year>2017</year>
            <month>Jul</month>
            <day>17</day>
            <volume>109</volume>
            <issue>12</issue>
            <fpage>933</fpage>
            <page-range>933-956</page-range>
            <pub-id pub-id-type="pmid">28714604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verrotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scaparrotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grosso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Anticonvulsant drugs and hematological disease.</article-title>
            <source>Neurol Sci</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>983</fpage>
            <page-range>983-93</page-range>
            <pub-id pub-id-type="pmid">24619070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18838.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mochizuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hamano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arakawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Imamura</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of a case with concurrent ingestion of carbamazepine overdose and grapefruit juice.</article-title>
            <source>Acute Med Surg</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-38</page-range>
            <pub-id pub-id-type="pmid">29123746</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
